Rising FDA Approvals by the Key Market Players to Drive the Arthritis Pain Management Market

The global arthritis pain management market is projected to exhibit considerable growth during the forecast period (2019-2025). The high prevalence of this arthritis disorder, the rapid increase in the R&D activities related to the drug development process for the treatment of this disorder by the key players operating is a major factor anticipated to fuel the arthritis pain management market during the forecast period. Johnson & Johnson Services Inc., F. Hoffman La Roche, Merck & Co. Inc., Sanofi SA, Pfizer Inc., Abbvie, Inc., Allergen PLC, Bayer AG, Amgen Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly and Co., Endo Pharmaceutical, Inc., and so on are the key market players operating in the global arthritis pain management industry.

Browse the full report description of "Global Arthritis Pain Management Market Size, Share & Trends Analysis Report by Drug Type (Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs (DMARDS), Corticosteroids, and Others), by End-User (Hospitals, Ambulatory Surgical Centres (ASCs), and Others) Forecast Period (2019-2025)" at https://www.omrglobal.com/industry-reports/arthritis-pain-management-market

These market players are making a hefty investment in their R&D sector to perform drug development for the launch of new and advanced drugs for the treatment of this disorder. For instance, in February 2020, GlaxoSmithKline Plc received FDA approval fordiclofenac sodium topical gel, 1% (Voltaren Arthritis Pain, GlaxoSmithKline) for temporary relief of arthritis pain. further, in June 2019, Eli Lili & Co. received FDA approval for baricitinib (Olumiant), used to get relief from arthritis pain. Baricitinib is a targeted disease-modifying antirheumatic drug (DMARD) that blocks Janus kinase (JAK), a group of enzymes that enable inflammatory signals to be activated inside a cell. 

In June 2017, Regeneron Pharmaceuticals, Inc., and Sanofi S.A. received FDA approval for Kevzara (sarilumab) injection to treat adults with moderate to severe rheumatoid arthritis (RA). Kevzara, a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), may be used as monotherapy or in combination with MTX or other DMARDs. This drug is given to the patient who had an inadequate response or intolerance to methotrexate (MTX-IR) drug. Thus, the increasing FDA approval for the drugs and therapy for the treatment of arthritis is anticipated to be a major factor to drive the growth of the global arthritis pain management market.

Current Market Trends Covered in the Market Report.

• North America is anticipated to hold a major market share during the forecast period.
• The rising awareness among people related to the treatment of arthritis including joint replacement
• Partnerships, collaborations, and new product launches – key drivers of competition in the market.

Global Arthritis Pain Management Market Segmentation

By Drug Type

• Anti-inflammatory biologics
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Corticosteroids
• Others

By End-User

• Hospitals
• Ambulatory Surgical Centres (ASCs)
• Others

Global Arthritis Pain Management Market Segmentation by region

North America

• United States
•  Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• Japan
•  India
• Rest of the Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

To learn more about this report request a free sample copy at  https://www.omrglobal.com/request-sample/arthritis-pain-management-market